Cite
HARVARD Citation
Ilhan, Y. et al. (2022). Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International journal of gynecological cancer. 32 (4), pp. 502-507. [Online].